BI-1206
BioInvent expands on its strategic portfolio shift
BioInvent has announced that it is reshaping its pipeline and focusing on its two most advanced clinical programs and pausing...
Intervju
BioInvent begins 2025 with positive clinical data
With several expected data readings from its four clinical...
Intervju
BioInvent expects a continued news-rich 2024
With a cash position of over one billion SEK...
BioInvent presents promising clinical data at ASCO and EHA
In the coming weeks, BioInvent will present...
BioInvent selected to present at ASCO in Chicago
BioInvent has been selected to present two posters...
BioInvent's CEO comments on the study success in China
BioInvent's partner in China, CASI Pharmaceuticals, has announced...
Intervju
BioInvent expects data from seven clinical studies in 2024
BioInvent entered 2024 with a solid...
BioInvent comments on progress in breast cancer study
BioInvent's pipeline consists of five drug candidates that are advancing...
Intervju
BioInvent is charging for presentations of clinical data
BioInvent reached a milestone in the third quarter...
BioInvent reaches research milestone in collaboration with Exelixis
BioInvent has reached a research milestone in its collaboration...
Intervju
BioInvent will soon have five drug candidates in six clinical studies
BioInvent has made a number of advances during the...
BioInvent's CFO on the company's business strategy
With a reported cash flow of just over 1,5 billion...
Intervju